Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis (2014)

Peer-Reviewed Study · Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M · December 2014

Seretny M et al., 2014-12: Meta-analysis of 31 studies and 4,179 patients estimating CIPN prevalence. It found about 68% in the first month after chemotherapy, falling to about 30% at six months or later.

CIPN prevalence was 68.1% (57.7-78.4) when measured in the first month after chemotherapy, 60.0% (36.4-81.6) at 3months and 30.0% (6.4-53.5) at 6months or more.

Abstract

Seretny M et al., 2014-12: Meta-analysis of 31 studies and 4,179 patients estimating CIPN prevalence. It found about 68% in the first month after chemotherapy, falling to about 30% at six months or later. Comparator: none (pooled prevalence). Funder/COI not in the abstract. The 68.1% first-month figure is the basis for 'up to 70%', but it is prevalence of any-grade CIPN across mixed regimens, and it falls to 30% beyond six months – so 'up to 70%' is defensible only for the period during/just after treatment. The paper also notes no effective prevention strategy and limited treatment of established chronic CIPN. Study type: review.